PMID- 25651730
OWN - NLM
STAT- MEDLINE
DCOM- 20150316
LR  - 20221207
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 60
IP  - 12
DP  - 2014
TI  - Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in 
      patients with type 2 diabetes mellitus.
PG  - 1969-76
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a serious threat to human health 
      and remains incurable. Insulin deficiency seems to be attributed to the 
      progressive failure of pancreatic islet beta-cells and immune cells such as T cells 
      mediated cytotoxicity may be involved in the loss of pancreatic islet beta-cells in 
      T2DM. Targeting on the immune system to maintain functional activity of 
      pancreatic islet beta-cells could be an attractive way to treat T2DM. Mesenchymal 
      stem cells (MSCs) exert potent capacity of immunomodulation. MSCs have been 
      successfully applied for the treatment of several types of autoimmune diseases. 
      So, the aim of this study is to evaluate the safety and potential therapeutic 
      effects of UMSC on T2DM. METHODS: UMSCs were separated, expanded, and identified 
      on the basis of the previous description. 18 patients of T2DM were recruited 
      according to our experimental protocol. UMSC was intravenously transfused three 
      times. All patients were followed up in the first, third, and sixth month. Age, 
      gender, diabetes duration and medications as well as weight, height, and BMI were 
      recorded. Fasting plasma glucose (FPG), postprandial blood glucose (PBG), HbA1c, 
      C-peptide, and subsets of T cells were measured. All adverse reactions were 
      carefully documented. Effective criteria were made and data was analyzed using 
      SPSS 19.0 software. RESULTS: UMSCs were successful obtained. Baseline clinical 
      characteristics between the efficacy and inefficacy groups were not statistically 
      different (p > 0.05). FBG and PBG of the patients in efficacy group were 
      significantly reduced (p < 0.05) after UMSC transfusion. Plasma C-peptide levels 
      and regulatory T (Treg) cell number in the efficacy group were numerically higher 
      after UMSC transfusion; however, the difference of both parameters did not reach 
      significance (p > 0.05). During the treatment course only 4 out of 18 patients 
      (22.2%) had slight transient fever. Up to 6 months after UMSC transfusion, all 
      patients continued to have a feeling of well-being and were physically more 
      active. CONCLUSIONS: UMSC transfusion is safe and well tolerated, effectively 
      alleviates blood glucose, and increases the generation of C-peptide levels and 
      Tregs in a subgroup of T2DM patients. This pilot study provides fundamental data 
      for further study of UMSC transfusion on control of blood glucose as well as 
      morbidity of T2DM in a larger cohort.
FAU - Kong, Dexiao
AU  - Kong D
FAU - Zhuang, Xianghua
AU  - Zhuang X
FAU - Wang, Daoqing
AU  - Wang D
FAU - Qu, Huiting
AU  - Qu H
FAU - Jiang, Yang
AU  - Jiang Y
FAU - Li, Xiaomei
AU  - Li X
FAU - Wu, Wenxiu
AU  - Wu W
FAU - Xiao, Juan
AU  - Xiao J
FAU - Liu, Xiaoli
AU  - Liu X
FAU - Liu, Junli
AU  - Liu J
FAU - Li, Ai
AU  - Li A
FAU - Wang, Juandong
AU  - Wang J
FAU - Dou, Aixia
AU  - Dou A
FAU - Wang, Yongjing
AU  - Wang Y
FAU - Sun, Junhua
AU  - Sun J
FAU - Lv, Hong
AU  - Lv H
FAU - Zhang, Guihua
AU  - Zhang G
FAU - Zhang, Xuhua
AU  - Zhang X
FAU - Chen, Shihong
AU  - Chen S
FAU - Ni, Yihong
AU  - Ni Y
FAU - Zheng, Chengyun
AU  - Zheng C
LA  - eng
SI  - ClinicalTrials.gov/NCT01413035
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - C-Peptide/blood
MH  - Cells, Cultured
MH  - China
MH  - *Cord Blood Stem Cell Transplantation/adverse effects
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*surgery
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects
MH  - Middle Aged
MH  - Pilot Projects
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2015/02/06 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/02/06 06:00
PHST- 2015/02/06 06:00 [entrez]
PHST- 2015/02/06 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - 10.7754/clin.lab.2014.140305 [doi]
PST - ppublish
SO  - Clin Lab. 2014;60(12):1969-76. doi: 10.7754/clin.lab.2014.140305.